From: Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma
Variables | p value | HR (95% CI) |
---|---|---|
(a) Univariate Cox regression model | ||
  Non-papillary gross finding | 0.076 | 1.82 (0.94–3.53) |
  Pathological T category ≥ 2 | 0.084 | 2.29 (0.89–5.87) |
  Pathological T category ≥ 3 | 0.012 | 2.54 (1.23–5.24) |
  High grade tumor | 0.95 | 1.12 (0.08–5.45) |
  Lymphovascular invasion |  < 0.0001 | 5.05 (2.43–10.50) |
  Concomitant subtype histology | 0.026 | 2.12 (1.10–4.12) |
  Concomitant carcinoma in situ | 0.61 | 0.81 (0.35–1.83) |
  Pathological lymph node metastasisa | 0.019 | 2.85 (1.19–6.84) |
  Positive surgical margin | 0.063 | 2.17 (0.96–4.98) |
  High budding |  < 0.0001 | 6.15 (3.12–12.1) |
  High TAICs (score 0–1) | 0.18 | 1.54 (0.82–2.91) |
  High periostin expression |  < 0.0001 | 5.90 (2.79–12.52) |
(b) Multivariate Cox regression model | ||
  Pathological T category ≥ 3 | 0.30 | 0.61 (0.24–1.54) |
  Lymphovascular invasion | 0.032 | 2.61 (1.08–6.27) |
  Concomitant subtype histology | 0.084 | 1.85 (0.92–3.72) |
  Pathological lymph node metastasisa | 0.91 | 1.05 (0.41–2.69) |
  High budding | 0.079 | 2.26 (0.91–5.63) |
  High periostin expression | 0.020 | 3.07 (1.19–7.88) |